Concepedia

A Phase I Biological and Pharmacologic Study of the Heparanase Inhibitor PI-88 in Patients with Advanced Solid Tumors

M. Basche, Daniel L. Gustafson, Scott N. Holden, Cindy L. O’Bryant, Lia Gore, Samir E. Witta, Mary Kay Schultz, Mark Morrow, Adrah Levin, Brian R. Creese,

Clinical Cancer Research · 2006 · 95 citations · 25 references

DOI

Abstract

The recommended dose of PI-88 administered for 4 consecutive days bimonthly or weekly is 250 mg/d. PI-88 was generally well tolerated. Evidence of efficacy in melanoma supports further evaluation of PI-88 in phase II trials.

References

25

New Guidelines to Evaluate the Response to Treatment in Solid Tumors

Patrick Therasse, Susan G. Arbuck, Elizabeth A. Eisenhauer et al. · JNCI Journal of the National Cancer Institute · 2000 · 15.7K citations

, , +17

Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer

Herbert I. Hurwitz, Louis Fehrenbacher, William Novotny et al. · New England Journal of Medicine · 2004 · 10.9K citations · Full text

A diagnostic test for heparin-induced thrombocytopenia

D Sheridan, C Carter, JG Kelton · Blood · 1986 · 698 citations · Full text

Identification of sulfated oligosaccharide-based inhibitors of tumor growth and metastasis using novel in vitro assays for angiogenesis and heparanase activity.

Christopher R. Parish, Craig Freeman, Kathryn J. Brown et al. · PubMed · 1999 · 400 citations

, , +19

Heparan Sulfate Degradation: Relation to Tumor Invasive and Metastatic Properties of Mouse B16 Melanoma Sublines

Motowo Nakajima, Tatsuro Irimura, Daniela Ferrante et al. · Science · 1983 · 347 citations

, , +21